Clinicopathological features and treatment strategy for triple-negative breast cancer

International Journal of Clinical Oncology

Volumn 15, Issue 4, 2010, Pages 341-351

  Yamamoto, Yutaka ^a   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Basal like breast cancer; Neoadjuvant chemotherapy; PARP1 inhibitors; Triple negative breast cancer

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; BEVACIZUMAB; BRCA1 PROTEIN; BSI 201; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; LEXATUMUMAB; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; SUNITINIB; TAXANE DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EARLY CANCER; FATIGUE; HISTOPATHOLOGY; HUMAN; LOCAL METASTASIS; MASTECTOMY; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REGIONAL METASTASIS; REVIEW; SURVIVAL TIME; TREATMENT PLANNING; TUMOR VASCULARIZATION; VISCERAL METASTASIS; VOMITING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77955715992     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0106-1     Document Type: Review

References (100)

1. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
2. Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer 109:1721-1728
3. Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376
4. Kwan ML, Kushi LH, Weltzien E et al (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11:R31
5. Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25-32
6. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502
7. Millikan RC, Newman B, Tse CK et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123-139
8. Iwase H, Kurebayashi J, Tsuda H et al (2010) Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 17:118-124
9. Gluz O, Liedtke C, Gottschalk N et al (2009) Triple-negative breast cancer-current status and future directions. Ann Oncol 20:1913-1927
10. Schneider BP, Winer EP, Foulkes WD et al (2008) Triplenegative breast cancer: Risk factors to potential targets. Clin Cancer Res 14:8010-8018
11. Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168-1176
12. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434
13. Tischkowitz M, Brunet JS, Begin LR et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134
14. Fulford LG, Reis-Filho JS, Ryder K et al (2007) Basal-like grade III invasive ductal carcinoma of the breast: Patterns of metastasis and long-term survival. Breast Cancer Res 9:R4
15. Dent R, Hanna WM, Trudeau M et al (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115:423-428
16. Fulford LG, Easton DF, Reis-Filho JS et al (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49:22-34
17. Harris LN, Broadwater G, Lin NU et al (2006) Molecular subtypes of breast cancer in relation to paclitaxel response, outcomes in women with metastatic disease: Results from CALGB 9342. Breast Cancer Res 8:R66
18. Freedman GM, Anderson PR, Li T et al (2009) Locoregional recurrence of triple-negative breast cancer after breastconserving surgery and radiation. Cancer 115:946-951
19. Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657
20. Kyndi M, Sorensen FB, Knudsen H et al (2008) Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 26:1419-1426
21. Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378
22. Voduc KD, Cheang MC, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691
23. Oakman C, Viale G, Di Leo A (2010) Management of triple negative breast cancer. Breast
24. Rakha EA, Putti TC, Abd El-Rehim DM et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208:495-506
25. Thike AA, Cheok PY, Jara-Lazaro AR et al (2010) Triplenegative breast cancer: Clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23:123-133
26. Viale G, Bottiglieri L (2009) Pathological definition of triple negative breast cancer. Eur J Cancer 45(Suppl 1):5-10
27. Jung SY, Kim HY, Nam BH et al (2010) Worse prognosis of metaplastic breast cancer patients than other patients with triplenegative breast cancer. Breast Cancer Res Treat 120:627-637
28. Stockmans G, Deraedt K, Wildiers H et al (2008) Triple-negative breast cancer. Curr Opin Oncol 20:614-620
29. Honma N, Saji S, Kurabayashi R et al (2008) Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast. APMIS 116:923-930
30. Bidard FC, Conforti R, Boulet T et al (2007) Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Ann Oncol 18:1285-1286
31. Diaz LK, Cryns VL, Symmans WF et al (2007) Triple negative breast carcinoma and the basal phenotype: From expression profiling to clinical practice. Adv Anat Pathol 14:419-430
32. Irvin WJ Jr, Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44:2799-2805
33. Kang SP, Martel M, Harris LN (2008) Triple negative breast cancer: Current understanding of biology and treatment options. Curr Opin Obstet Gynecol 20:40-46
34. Kreike B, van Kouwenhove M, Horlings H et al (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65
35. Lerma E, Peiro G, Ramon T et al (2007) Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol 20:1200-1207
36. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: A critical review. Histopathology 52:108-118
37. Shiu KK, Tan DS, Reis-Filho JS (2008) Development of therapeutic approaches to 'triple negative' phenotype breast cancer. Expert Opin Ther Targets 12:1123-1137
38. Toyama T, Yamashita H, Kondo N et al (2008) Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer 8:309
39. Tan DS, Marchio C, Jones RL et al (2008) Triple negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 111:27-44
40. Sanchez-Munoz A, Gallego E, de Luque V et al (2010) Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer 10:136
41. Bergamaschi A, Kim YH, Wang P et al (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45:1033-1040
42. Jones C, Nonni AV, Fulford L et al (2001) CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 85:422-427
43. Korsching E, Packeisen J, Agelopoulos K et al (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82:1525-1533
44. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
45. Bertucci F, Finetti P, Cervera N et al (2008) How basal are triple-negative breast cancers? Int J Cancer 123:236-240
46. Kim MJ, Ro JY, Ahn SH et al (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37:1217-1226
47. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374
48. Rakha EA, Elsheikh SE, Aleskandarany MA et al (2009) Triplenegative breast cancer: Distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2302-2310
49. Yamamoto Y, Ibusuki M, Nakano M et al (2009) Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 16:260-267
50. Turner N, Tutt A, Ashworth A (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819
51. Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348:2339-2347
52. Linn SC, Van 't Veer LJ (2009) Clinical relevance of the triplenegative breast cancer concept: Genetic basis and clinical utility of the concept. Eur J Cancer 45(Suppl 1):11-26
53. Foulkes WD, Brunet JS, Stefansson IM et al (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/ p53?/glomeruloid- microvascular-proliferation?) phenotype of BRCA1-related breast cancer. Cancer Res 64:830-835
54. Crook T, Brooks LA, Crossland S et al (1998) p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 17:1681-1689
55. Richardson AL, Wang ZC, De Nicolo A et al (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9:121-132
56. Tirkkonen M, Johannsson O, Agnarsson BA et al (1997) Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57:1222-1227
57. Futreal PA, Liu Q, Shattuck-Eidens D et al (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122
58. Turner NC, Reis-Filho JS, Russell AM et al (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26:2126-2132
59. Bidard FC, Matthieu MC, Chollet P et al (2008) p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol 19:1261-1265
60. Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334
61. Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281
62. Di Leo A, Isola J, Piette F et al (2009) A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Cancer Res 69 (abstract 705)
63. Cheang M, Chia SK, Tu D et al (2009) Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 27 (abstract 519)
64. Hayes DF, Thor AD, Dressler LG et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506
65. Ellis P, Barrett-Lee P, Johnson L et al (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): An open-label, phase III, randomised controlled trial. Lancet 373:1681-1692
66. Bhattacharyya A, Ear US, Koller BH et al (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899-23903
67. Tassone P, Tagliaferri P, Perricelli A et al (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285-1291
68. Silver DP, Richardson AL, Eklund AC et al (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153
69. Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379
70. Koshy N, Quispe D, Shi R et al (2010) Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast Mar 11 [Epub ahead of print]
71. http://clinicaltrials.gov/ct2/show/NCT00532727
72. D'Amours D, Desnoyers S, D'Silva I et al (1999) Poly(ADPribosyl) ation reactions in the regulation of nuclear functions. Biochem J 342(Pt 2):249-268
73. Helleday T, Bryant HE, Schultz N (2005) Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4:1176-1178
74. Tutt A RM, Garber JE, Domchek S, et al. (2009) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 27 (abstract 501)
75. O'Shaughnessy J OC, Pippen J, Yoffe M et al (2009) Efficacy of BSI-201, a PARP Inhibitor, in combination with gemcitabine/ carboplatin in triple negative metastatic breast cancer: Results of a phase II study. J Clin Oncol 27 (abstract 3)
76. http://clinicaltrials.gov/ct2/show/NCT00938652
77. Dubois EA, Cohen AF (2009) Trabectedin. Br J Clin Pharmacol 68:320-321
78. Delaloge S TK, Blum J, Gonçalves A et al (2009) Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). J Clin Oncol 27 (abstract 1010)
79. Carey LA, Rugo HS, Marcom PK et al (2009) TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 27 (abstract 1009)
80. Normanno N, Campiglio M, Maiello MR et al (2008) Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast Cancer Res Treat 112:25-33
81. Normanno N, De Luca A, Maiello MR et al (2006) The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 207:420-427
82. Linderholm BK, Hellborg H, Johansson U et al (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20:1639-1646
83. Ryden L, Jirstrom K, Haglund M et al (2010) Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat 120:491-498
84. Ryan PD, Tung NM, Isakoff SJ et al (2009) Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. J Clin Oncol 27 (abstract 551)
85. Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816
86. http://clinicaltrials.gov/ct2/show/NCT00861705
87. http://clinicaltrials.gov/ct2/show/NCT00528567
88. Finn RS, Dering J, Ginther C et al (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/''triple-negative'' breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105:319-326
89. Finn RS, Bengala C, Ibrahim N et al (2009) Phase II trial of dasatinib in triple-negative breast cancer: Results of study CA180059. Cancer Res 69 (abstract 3118)
90. Livasy CA, Karaca G, Nanda R et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264-271
91. Le Tourneau C, Dettwiler S, Laurence V et al (2007) 47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients. Breast Cancer Res Treat 106 (abstract 4010)
92. Keam B, Im SA, Kim HJ et al (2007) Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: Paradoxical features of the triple negative breast cancer. BMC Cancer 7:203
93. Toi M, Nakamura S, Kuroi K et al (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110:531-539
94. Darb-Esfahani S, Loibl S, Muller BM et al (2009) Identification of biology-based breast cancer types with distinct predictive and prognostic features: Role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/ taxane-based chemotherapy. Breast Cancer Res 11:R69
95. Straver ME, Glas AM, Hannemann J et al (2010) The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 119:551-558
96. Sirohi B, Arnedos M, Popat S et al (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19:1847-1852
97. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685
98. Rody A, Karn T, Solbach C et al (2007) The erbB2? cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 16:235-240
99. de Ronde JJ, Hannemann J, Halfwerk H et al (2009) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119-126
100. Chappuis PO, Goffin J, Wong N et al (2002) A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 39:608-610